https://repositorio.fleni.org.ar/xmlui/handle/123456789/29 Sun, 05 Apr 2026 17:43:29 GMT 2026-04-05T17:43:29Z https://repositorio.fleni.org.ar/xmlui/handle/123456789/1457 Radioterapia hipofisaria Katz, Débora Adela Thu, 01 Jan 2026 00:00:00 GMT https://repositorio.fleni.org.ar/xmlui/handle/123456789/1457 2026-01-01T00:00:00Z https://repositorio.fleni.org.ar/xmlui/handle/123456789/1448 Adenomas hipofisiarios: ¿qué nos aporta la detección de factores de transcripción a la práctica clínica? Slavinsky, Patricia; González Pernas, Mariana; Battistone, María Florencia; Pingel, Jésica; Sevlever, Gustavo Emilio; Arakaki, Naomi; Mezmezian, Mónica Beatriz; Rojas, Estefanía; Schultz, Marcelo; Cervio, Andrés Eduardo; Katz, Débora Adela Resumen no disponible Thu, 26 Sep 2024 00:00:00 GMT https://repositorio.fleni.org.ar/xmlui/handle/123456789/1448 2024-09-26T00:00:00Z https://repositorio.fleni.org.ar/xmlui/handle/123456789/1369 Refining pituitary adenoma classification: the role of transcription factors in diagnosis and risk assessment Katz, Débora Adela; Slavinsky, Patricia; Pernas, Mariana Gonzalez; Battistone, Maria Florencia; Pingel, Jesica; Arakaki, Naomi; Mezmezian, Mónica Beatriz; Sevlever, Gustavo Emilio; Rojas, Estefanía; Schultz, Marcelo; Cervio, Andrés Eduardo JOINT1942 Introduction: The new classification of pituitary tumors (WHO 2022) is based on transcription factors (TF) detected through immunohistochemistry (IHC) to determine tumor lineage. The aim of our study was to evaluate the usefulness of incorporating the WHO 2022 classification into the pathological study of pituitary adenomas (PA). Materials and Methods: We retrospectively analyzed records of adults with PA who underwent surgery between January 2023 and December 2024. Clinical, radiological (tumor size, cavernous sinus invasion), and histopathological data were reviewed, including IHC for hormones and TF: SF1, Tpit, Pit1, GATA3, and Ki-67%. High-risk PAs were identified according to WHO 2022 criteria. Tumors were classified as invasive if they had Knosp grade III or IV. Results: A total of 112 tumor samples were included. The majority belonged to the SF1 lineage (50%), followed by Pit1 (29%), TPIT (21%). With the incorporation of TF analysis, the diagnosis was modified in 19 patients:. • 11 clinically non-functioning adenomas (CNFA) with negative hormonal IHC were reclassified as gonadotropinomas (SF1+; n = 7), 1 corticotropinoma (TPIT+) and 1 null cell. • Only 2 CNFA were triple-negative but GATA3+. • 5 patients with acromegaly were reclassified as: 1 immature, 1 mature Pit1 lineage tumor, 2 acidophil stem cell tumors, and 1 plurihormonal (Pit1 and SF1). • 2 patients with thyrotropinoma were reclassified as immature and mature Pit1 lineage tumors. • 1 CNFA with IHC for PRL and GH was re3. • classified as plurihormonal (Pit1 and SF1). • 43 gonadotropinomas, 2 corticotropinomas, 1 acidophil stem cell, 3 Pit-1, and a plurihormonal tumor were GATA3+. • 31 patients with high-risk histological subtype tumors (7 reclassified with TF). These tumors were associated with invasiveness in 48% and Ki-67 ≥ 3% in 6.4%. • 81 patients with low-risk histology: 38% were invasive, and 3.7% had Ki-67 ≥ 3%. Conclusions: The addition of IHC for TF to routine diagnostics allows a more accurate classification of pituitary adenomas, particularly in cases with absent or low hormonal expression. IHC for GATA3 could be a useful marker for diagnosing gonadotropinomas and certain immature tumors. Diagnosing Pit1 adenomas presents challenges due to variability in hormonal expression, coexpression of transcription factors, and distinction between mature and immature types. The classification of tumors into high- and low-risk groups provides an additional parameter for individualized risk assessment, which should be considered along with clinical, radiological, and histopathological factors. These findings reinforce the need for molecular techniques to refine PitNET classification and enhance diagnostic precision. Keywords: pituitary neoplasms, tumor classification, WHO 2022. Mon, 10 Mar 2025 00:00:00 GMT https://repositorio.fleni.org.ar/xmlui/handle/123456789/1369 2025-03-10T00:00:00Z https://repositorio.fleni.org.ar/xmlui/handle/123456789/1183 Pituitary metastases: a diagnostic and therapeutic challenge Loto, Mónica; Rogozinski, Amelia; Alfieri, Analía; Ballarino, María Carolina; Battistone, María Florencia; Chervin, Alberto B.; Danilowicz, Karina; Diez, Sabrina; Fainstein Day, Patricia; Furioso, Alejandra; Glerean, Mariela; González Pernas, Mariana Soledad; Katz, Débora Adela; Mallea-Gil, María Susana; Martínez, Marcela; Miragaya, Karina; Sabate, María Isabel; Slavinsky, Patricia; Sosa, Soledad; Szuman, Gabriela; Tkatch, Julieta; Vitale, Nicolás Marcelo; Guitelman, Mirtha Introduction: Sellar metastases (SM) are rare manifestations of malignancy. Breast and lung cancer are the most common primary tumors. Most cases are diagnosed in patients with advanced malignant disease; however, symptoms of pituitary involvement can precede the diagnosis of the primary tumor. Methods: Retrospective analysis of symptoms at presentation, hormonal, radiological and histological findings, management, and outcome of patients with SM from 2009 to 2020. Results: Eighteen patients'cases were included, 11 with histological confirmation. Median (m) age was 53 years (range 35-75), 53% male. Primary malignant tumors: 8 lungs, 6 breast, 1 follicular thyroid carcinoma, 1 Hodgkin lymphoma, and 2 clear cell renal carcinomas. The m time between the diagnosis of the primary neoplasm and the occurrence of the SM was 108 months (range: 11-180). In 8 patients the diagnosis of the primary neoplasm was made after the finding of the symptomatic sellar mass. Insipidus diabetes, adenohypophysis deficit, visual disorders, headache, and cranial nerve deficits were evident in 78, 77, 61, 39 and 39% of the cases, respectively. Fifteen patients harbored supra / parasellar masses, in three a lesion was limited to the pituitary gland, and stalk. Eleven out of 18 (61.1%) of the patients were operated on by the trans-sphenoidal approach, for diagnostic and / or decompressive purposes. Eighteen died, with a median survival time of 6 months (1-36). Discussion: In the presence of a pituitary lesion with diffuse gadolinium uptake, associated with insipidus diabetes and / or visual disorder SM should be suspected even in patients without a history of oncological disease. Mon, 01 Jan 2024 00:00:00 GMT https://repositorio.fleni.org.ar/xmlui/handle/123456789/1183 2024-01-01T00:00:00Z